Four-Year-Old Critically Ill With Meningococcal Infection in Israel

A four-year-old child from Holon is in serious condition at Wolfson Medical Center after contracting a severe meningococcal infection. The child was admitted to the pediatric emergency department with rapidly developing symptoms, which doctors diagnosed as invasive meningococcal disease. Dr. Diana Tcher, head of the pediatric department at Wolfson, described the infection as one of the most aggressive and rapidly progressing known in pediatrics, capable of overwhelming a healthy person within hours and leading to organ failure and a life-threatening condition.

Meningococcus bacteria typically reside in the nasopharynx and can transition from a passive state to active disease, entering the bloodstream or nervous system to cause meningitis or sepsis. Dr. Tcher explained that early symptoms are often non-specific, resembling a common viral illness like fever, weakness, or body aches. However, the disease can progress extremely rapidly, making prompt diagnosis and treatment critical.

The infection primarily affects children under two years old, as well as those in crowded conditions or with weakened immune systems. Dr. Tcher urged parents and healthcare workers to be vigilant for warning signs such as neck stiffness, apathy, or a non-blanching petechial rash, and to seek immediate medical attention if these appear.

This case follows the deaths of two young children from meningococcal infections in June, one at Ichilov Hospital and another at Soroka Hospital. The incident has reignited debate over the Bexsero vaccine against meningococcal group B, which is not part of Israel's national infant vaccination program. While recommended by the Ministry of Health and the Pediatric Association for children under two, it is only available privately through supplementary health insurance at a cost of several hundred shekels per dose, with a full course requiring three doses.

The Bexsero vaccine has been presented to the National Health Basket Committee seven times for inclusion in the national program but has been repeatedly rejected. Committee members cited the high cost of approximately 63 million shekels for the program, arguing the benefits are limited compared to the expense. Opponents also noted that meningitis can be caused by various pathogens, and Bexsero only protects against group B. Data from the Ministry of Health shows that in 2025, Israel recorded 56 meningococcal cases, with only eight caused by group B, and both recorded fatalities were from other groups. Furthermore, adding a three-dose vaccine would strain the capacity of mother and child health centers, especially after the recent addition of RSV immunizations to the national program.